Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia
NCT00001406 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 800
Last updated 2026-05-22
Summary
This study will investigate how, why and under what conditions eosinophils (a type of white blood cell) become activated and will examine their function in immune reactions. Eosinophil counts often rise in response to allergies, asthma, and parasitic worm infections. They can also go up in uncommon autoimmune conditions and, rarely, in association with tumors. Elevated levels of these cells is called eosinophilia. Usually, eosinophilia causes no apparent symptoms, but in rare cases there may be local swelling and itching, allergic lung problems, heart disease or nerve damage caused by the release of toxic substances in these cells into body tissues.
Patients 1 to 100 years of age with eosinophil counts greater than 750/ml or an abnormal accumulation of eosinophils in the skin or body tissues may be eligible for this study. All participants will have a thorough medical history, physical examination and blood tests. Depending on the person's age and symptoms, other diagnostic tests may be done, including specialized studies of the eye, lungs, skin, bone marrow, nerves or heart. This is not a treatment study, and no experimental treatments will be offered. Patients who require treatment will receive standard medical care.
Certain other procedures may be requested solely for research purposes. All participants will be asked to donate extra blood for laboratory studies investigating how immune cells and other immune substances in the blood act to stimulate a rise in eosinophils. In addition, some participants may undergo one or more of the following:
* Annual Follow-up evaluations - Physical examinations and blood tests to evaluate changes in the patient's condition and eosinophil counts over time.
* Bone marrow biopsy and aspiration will be recommended during the initial evaluation, and in certain patients at other times when it is important to look directly at the newly developing cells in the bone marrow. For this procedure an area of skin and bone is anesthetized with xylocaine (an anesthetic similar to that used by dentists), and a very sharp needle is used to sample the bone marrow for evaluation. Bone marrow biopsy and aspiration can have side effects of pain and/or bleeding into the skin and soft tissues at the site of the procedure. Rarely the area at the biopsy site can become infected, and is treated with antibiotics.
* Genetic testing: Some of the blood drawn from you as part of this study will be used for genetic tests. Genetic tests can help researchers study how health or illness is passed on to you by your parents or from you to your children. Any genetic information collected or discovered about you or your family will be confidential.
* Leukapheresis (only patients 18 years and older) to collect large numbers of certain cells - In this procedure, whole blood is collected through a needle placed in an arm vein. The blood circulates through a machine that separates it into its components. The white cells are then removed and the rest of the blood is returned to the body, either through the same needle used to draw the blood or through a second needle placed in the other arm....
Conditions
- Immune System Diseases
- Eosinophilia
- Helminthiasis
- Hypersensitivity
- Parasitic Disease
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Principal Investigators
-
Amy D Klion, M.D. · National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility
- Min Age
- 1 Year
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1997-04-21
Countries
- United States
Study Locations
More Related Trials
-
Role of Circulating Innate Lymphoid Cells in Allergic Disorders
NCT03069495 ·Status: TERMINATED
-
Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
NCT00086658 ·Status: COMPLETED ·Phase: PHASE3
-
Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis
NCT00635089 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Mast Cell Precursors
NCT00001756 ·Status: COMPLETED
-
Eosinophilia Diagnosis
NCT02581514 ·Status: UNKNOWN ·Phase: NA
-
A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
NCT03496571 ·Status: COMPLETED ·Phase: PHASE2
-
Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis
NCT02775045 ·Status: COMPLETED
-
A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis
NCT05084963 ·Status: COMPLETED ·Phase: PHASE2
-
An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis
NCT03664960 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)
NCT02379052 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy
NCT00329381 ·Status: COMPLETED ·Phase: PHASE4
-
Immunological Mechanisms Underlying Mucosal IgE Responses
NCT06234761 ·Status: RECRUITING
-
Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
NCT02836496 ·Status: COMPLETED ·Phase: PHASE3
-
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
NCT03801434 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
NCT00691873 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL
NCT01544348 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
NCT04322604 ·Status: COMPLETED ·Phase: PHASE3
-
EoE Food Test Pilot Study
NCT07023380 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis
NCT05152563 ·Status: WITHDRAWN ·Phase: PHASE3
-
The Effect of Xolair (Omalizumab) on Allergy Blood Cells
NCT00657891 ·Status: COMPLETED ·Phase: PHASE4
-
Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis
NCT00001761 ·Status: COMPLETED ·Phase: PHASE1
-
Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome
NCT00266565 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils
NCT02023151 ·Status: COMPLETED ·Phase: PHASE4
-
Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria
NCT02814630 ·Status: COMPLETED ·Phase: NA
-
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis
NCT04856891 ·Status: COMPLETED ·Phase: PHASE3